今日要闻！2023中国电影美学年会顺利召开：聚焦美学创新 探索电影发展新路径

2023中国电影美学年会顺利召开：聚焦美学创新 探索电影发展新路径

北京 - 2023年9月26日 - 由中国电影艺术研究中心主办的2023中国电影美学年会于今日在北京召开。来自全国各地的电影学者、导演、编剧、演员等百余位电影人齐聚一堂，共同探讨中国电影美学创新与发展。

年会以“美学创新·发展之路”为主题，聚焦中国电影美学建设的重大理论和实践问题，深入探讨电影美学创新与电影发展新路径。与会嘉宾围绕电影美学创新、类型电影美学、地域电影美学、新媒体电影美学等议题进行了热烈讨论，并分享了各自的研究成果和实践经验。

中国电影艺术研究中心副主任王海斌在致辞中表示，电影美学是电影艺术的核心内容，也是电影发展的灵魂。近年来，中国电影美学建设取得了长足进步，涌现出一批优秀的美学成果。但与此同时，电影美学创新也面临着新的挑战。

王海斌指出，要推动中国电影美学创新，必须坚持以人民为中心的创作导向，坚持守正创新、求同存异，坚持走中国特色电影美学发展道路。

著名电影学者张辉在主题演讲中表示，电影美学创新要紧跟时代步伐，反映时代风貌，满足时代需求。要以社会主义核心价值观为引领，弘扬中华民族优秀传统文化，增强文化自信。

导演贾樟柯在发言中表示，电影美学创新要打破套路，敢于突破，勇于探索。要尊重观众审美需求，提供更多优质的电影作品。

编剧刘震云在发言中表示，电影美学创新要注重故事的讲述，塑造鲜活的人物形象。要深入生活，扎根人民，创作出具有现实意义和艺术感染力的作品。

演员黄渤在发言中表示，电影美学创新要注重表演的艺术性，追求表演的真实性和感染力。要不断磨练演技，塑造出具有感染力的电影角色。

年会还进行了电影美学创新成果展映和电影美学创新论坛等活动。通过本次年会，电影界进一步凝聚了共识，增强了信心，为推动中国电影美学创新与发展奠定了坚实的基础。

以下是一些关于年会的更多信息：

• 主办单位：中国电影艺术研究中心
• 承办单位：北京电影学院
• 时间：2023年9月26日
• 地点：北京
• 主题：美学创新·发展之路

2023中国电影美学年会的顺利召开，为中国电影美学创新与发展注入了新的活力。相信在电影界同仁的共同努力下，中国电影将创造出更加辉煌的成绩。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.